Helapet introduce new, improved 20mm Vented Vial Adapter
Helapet have launched an improved 20mm Vented Vial Adapter, introducing a larger integrated air filter for rapid and reliable venting performance when drawing-up cytotoxic drugs and other hazardous medical solutions (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 1, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News cytotoxic drugs hazardous medical solutions helapet Latest News vented vial adapter vial venting Source Type: news
Bio Products Laboratory Receives European Approval for Coagadex ®
First-ever treatment for rare bleeding disorder ‘hereditary factor X deficiency’ approved in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 31, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Haematology Patient care bleeding disorder coagadex coagulant factor X Latest News Source Type: news
Bio Products Laboratory Receives European Approval for Coagadex®
First-ever treatment for rare bleeding disorder ‘hereditary factor X deficiency’ approved in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 31, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Haematology Patient care bleeding disorder coagadex coagulant factor X Latest News Source Type: news
Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab
Ten independent studies validate the growing bank of real-life clinical evidence to support switching patients from the reference infliximab (Remicade®) to biosimilar infliximab (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 22, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Healthcare professionals Practical therapeutics Patient care Research European Crohn ’s and Colitis Organisation ibd immunogenicity infliximab Latest News remicade switching ulcerative colitis Source Type: news
LEO Pharma recieves scientific approval of Enstilar® for the treatment of psoriasis in EU
The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 21, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Dermatology Patient care calcipotriol/betamethasone dipropionate enstilar fixed combination topical foam Latest News psoriasis vulgaris Source Type: news
BD receives CE mark for next generation blood separation technology
BD Vacutainer® Barricor™ Tube designed to enhance sample quality, improve laboratory efficiency and speed laboratory turnaround time (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 21, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Medical Devices Haematology BD Vacutainer Barricor Tube laboratory turnaround time Latest News Source Type: news
Greater survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Janssen announced that data from a post-hoc analysis of the Phase III COU-AA-302 trial showed that ZYTIGA® plus prednisone provided an 11.8 months overall survival benefit, compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 14, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care advanced prostate cancer COU-AA-302 trial European Association of Urology Latest News mCRPC Zytiga Source Type: news
SMC accepts breakthrough treatment Entresto™ for use in patients with symptomatic chronic heart failure
Sacubitril/valsartan represents a breakthrough therapeutic option for adult patients with symptomatic chronic heart failure with reduced ejection fraction (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Healthcare professionals Practical therapeutics Cardiovascular medicine Patient care chronic heart failure Latest News sacubitril/valsartan scottish medicines consortium Source Type: news
Novartis’ Cosentyx® superior to Stelara in delivering lasting skin clearance for psoriasis patients
Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Dermatology Patient care Research ankylosing spondylitis Cosentyx Latest News PASI psoriatic arthritis Source Type: news
Allergan completes transfer of European MA for Ironwood’s CONSTELLA® from Almirall S.A
CONSTELLA® is the only available prescription treatment with a European Marketing Authorisation specifically for irritable bowel syndrome with constipation (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 3, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Gastroenterology Patient care constella constipation IBS-C irritable bowel syndrome Latest News marketing authorisation Source Type: news
New immunotherapy trial launched to test cancer vaccine
Vaccine activates body’s own immune system to fight cancer (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 2, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care Research cancer vaccine immunotherapy Latest News VAPER trial Source Type: news
Prostrakan and AstraZeneca enter into agreement for rights to Moventig® in Europe
Moventig is the first once-daily, oral peripherally acting mu-opioid receptor antagonist approved in Europe for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s) (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 1, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Gastroenterology Oncology Pain management Patient care Latest News laxatives moventig naloxegol oic opioid induced constipation PAMORA Source Type: news
Sobi supports The Rare Project to increase awareness about rare diseases
To highlight Rare Disease Day 2016 on 29 February, Swedish Orphan Biovitrum Ltd. (Sobi) is proud to sponsor 'The Rare Project', a project initiated by the not for profit organisation Same But Different (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 24, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Paediatrics Latest News rare disease day same but different the rare project Source Type: news
